Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2009 | Original Paper

2008 update of the guideline: early detection of breast cancer in Germany

Authors: Ute-Susann Albert, Helmut Altland, Volker Duda, Jutta Engel, Max Geraedts, Syvia Heywang-Köbrunner, Dieter Hölzel, Eva Kalbheim, Michael Koller, Klaus König, Rolf Kreienberg, Thorsten Kühn, Annette Lebeau, Irmgard Nass-Griegoleit, Werner Schlake, Rita Schmutzler, Ingrid Schreer, Hilde Schulte, Rüdiger Schulz-Wendtland, Uwe Wagner, Ina Kopp

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2009

Abstract

Introduction

The goal of the 2008 updated guideline: early detection of breast cancer in Germany is to support physicians as well as healthy and affected women in the decision-making process involved in the diagnostic chain for the early detection of breast cancer by providing them with evidence- and consensus-based recommendations. The updated guideline replaces the guideline issued in 2003.

Materials and methods

The guideline forms the basis for developing an effective and efficient national early breast cancer detection program that meets the standards set by the Council of Europe and WHO for cancer control programs. The guideline presents the current, evidence- and consensus-based state of scientific knowledge in a multidisciplinary approach for the entire diagnostic chain, consisting of history taking and risk consultation, information on health behavior, clinical breast examination, diagnostic imaging, image-guided percutaneous tissue-acquisition techniques, open surgical excisional biopsy and pathomorphological tissue evaluation. The guideline recommends a set of quality indicators to assure resource availability, performance quality and outcomes enhancing total quality management for early breast cancer diagnosis.

Conclusion

Currently, early detection of breast cancer offers the most promising possibility to optimize the diagnosis and treatment of breast cancer and, as a result, reduce breast cancer mortality and improve health related quality of life in women.

Albert US (ed) (2008) Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland 1.Aktualisierung 2008, 1st edn. Zuckschwerdt, Muenchen

Albert US, Schulz KD, The members of the guideline steering committee and the chair persons of the task force groups (2004) Short version of the guideline: early detection of breast cancer in Germany. J Cancer Res Clin Oncol 130:527–536. doi:10.1007/s00432-004-0558-7 PubMedCrossRef

Albert US, Schulz KD, Alt D, Beck V, Doherty J, Holsteg K et al (2003) Eine Leitlinie für Leitlinien: die methodische Entwicklung und Anwendung der Leitlinie Fraueninformation. Zentralbl Gynakol 125:484–493 (AWMF Reg. Nr.: 077-002; http://www.awmf-leitlinien.de)

Albert US, Schulz KD, Kopp I (2007) Leitlinien-Methodenreport: Aktualisierung der Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland 2007, konsultierte Fassung Version 1.1 edn. http://www.awmf-leitlinien.de, Marburg

Amendoeira I, Apostolikas N, Bellocq J, Bianchi S, Boecker W, Borisch B, Elston C, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquermier J, Lacerda M, Martinez-Penuela J, De Miquel C, Nordgren H, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafari B, Tanous A, Thorstenson S, Zozoya E, Wells C (2006a) Quality assurance guidelines for pathology: Cytological and histological non-operative procedures. In: Wells CA (ed) European guidelines for quality assurance in breast cancer screening and diagnosis, 4 edn. Office for Official Publications of the European Communities, Luxembourg, pp 221–256

Amendoeira I, Apostolikas N, Bellocq J, Bianchi S, Boecker W, Borisch B et al. 0, Elston C, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquermier J, Lacerda M, Martinez-Penuela J, De Miquel C, Nordgren H, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafari B, Tanous A, Thorstenson S, Zozoya E, Wells C (2006b) Quality assurance guidelines for pathology: open biopsy and resection specimens. In: Wells CA (ed) European guidelines for quality assurance in breast cancer screening and diagnosis, 4 edn. Office for Official Publications of the European Communities, Luxembourg, pp 257–311

American College of Radiology (ACR) (2003) Breast Imaging reporting and data system (BIRADS™), 4th edn. American College of Radiology, Reston, VA

Ball C, Sackett D, Philipps B, Haynes B, Straus S, Dawes M (2001) Oxford-Centre for Evidence-based Medicine Levels of Evidence (2001). http://www.cebm.net/level_of_evidence.asp Zugriff: 08042007

Brenner H, Stegmaier C, Ziegler H (2005) Verbesserte Langzeitüberlebensraten von Krebspatienten. Die unterschätzten Fortschritte der Onkologie. Dtsch Arztebl 102:2628–2633

Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005) The psychological impact of mammographic screening. A systematic review. Psychooncology 14:917–938. doi:10.1002/pon.904 PubMedCrossRef

Bundesärztekammer (BÄK) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV) (2007) Nationales Programm für VersorgungsLeitlinien. Methoden-Report, 3rd edn. Berlin, http://www.versorgungsleitlinie.de

Calman K, Hine D, Peto R, Boreham J, Clarke M, Purushotham A, Pain S, Miles D (2002) NICE: Improving outcomes in breast cancer. NICE, London

Carlson R, Anderson B, Burstein H (2005) NCCN Breast Cancer Clinical practice guidelines in Oncology. National Comprehensivie Cancer Network (http://www.nccn.org), USA

Crystal P, Koretz M, Shcharynsky S, Makarov V, Strano S (2004) Accuracy of sonographically guided 14-gauge core-needle biopsy: result of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions. J Clin Ultrasound 33:47–51. doi:10.1002/jcu.20089 CrossRef

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410. doi:10.1111/j.1365-2559.1991.tb00229.x PubMedCrossRef

Encke A, Kopp I, Selbmann H, Hoppe J, Köhler A, Ollenschläger G (2006) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), (Hrsg) (2006) Deutsches Instrument zur methodischen Bewertung von Leitlinien: DELBI. Dt Ärztebl 102:A1912–A1913

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2006) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581–592. doi:10.1.093/annonc/imd498 CrossRef

Fishman J, Milikowski C, Ramsinghani R, Velasquez M, Aviram G (2003) US-guided core-needle biopsy of the breast: how many specimens are necessary? Radiology 226:779–782PubMedCrossRef

Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.und das Robert Koch Institut (2006) Krebs in Deutschland - Häufigkeiten und Trends, 5. überarbeitete, aktualisierte Auflage edn. RoBo Print, Riegelsberg, Saarbrücken

Gotzsche PC, Nielsen M (2006) Screening for breast cancer with mammography. Cochrane Database Syst Rev 18(4):CD001877. doi:10.1002/14651858.CD001877.pub2

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed

Hoffmann W, Latza U, Terschüren C, Berger K, Bergmann M, Dahl A et al. (2004) Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP) - Langversion, 2.mit Änderungen nach Evaluation edn. Arbeitsgruppe Epidemiologischer Methoden der Deutschen Arbeitsgemeinschaft für Epidemiologie (DAE); Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS); Deutsche Gesellschaft für Sozialmedizin und Prävention (DGSMP); Deutsche Regionen der Internationalen Biometrischen Gesellschaft (DR-IBS); 1.ed: Kurth BM; Hense HW; Hoffmann W; AhrensW; Babitsch B; Becher H; Blettner M; Brasche S; Brenner H; Enderlein G; Greiser KH; Jahn I; Jöckel KH; Kirschner W; Kohlmann T; Liese A; Möhner M; Mueller U; Reintjes R; Stang A; Wyst M: http://www.medweb.uni-muenster.de/institute/epi/dae/vorstand.html, Münster

ICSI (2005) Diagnosis of breast disease—guideline ICSI, update 2005. ICSI, (http://www.icsi.org)

Katalinic A, Bartel C, Raspe H, Schreer I (2007) Beyond mammography screening: quality assurance in breast cancer diagnosis. Br J Cancer 96:157–161PubMedCrossRef

Kopp I, Encke A, Lorenz W (2002) Leitlinien als Instrument der Qualitätssicherung in der Medizin. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 45:223–233. doi:10.1007/s00103-002-0378-3 CrossRef

Lorenz W, Ollenschläger G, Geraedts M, Gerlach F, Gangjour A, Helou A et al (2001) Das Leitlinien Manual:Entwicklung und Implementierung von Leitlinien in der Medizin. ZaeFQ 95:1–84

Madjar H, Ohlinger R, Mundinger A, Watermann D, Frenz J, Bader W et al (2006) BI-RADS analoge DEGUM Kriterien von Ultraschallbefunden der Brust - Konsensus des Arbeitskreises Mammosonographie der DEGUM. Ultraschall Med 27:374–379. doi:10.1055/s-2006-926943 PubMedCrossRef

NBCC (2004a) Clinical practice guidelines for the management and support of younger women with breast cancer, 1st edn. National Health and Medical Research Council (NHMRC), (http://www.nbcc.org.au), Camperdown, NSW

NBCC (2004b) Position Statement early detection of breast cancer. In: NBCC (ed) National Health and Medical Research Council, (http://www.nbcc.org.au), Canberra

NBCC (2006) The investigation of a new breast syptom—a guide for GP. NBCC, http://www.nbcc.org.au, Australia

National Breast Cancer Center (NBCC) (2001) Clinical practice guidelines for the management of early breast cancer, i Soruce edn. National Breast Cancer Center (NBCC) (http://www.nbcc.org.au), Australia

National Breast Cancer Centre (NBCC) (2006) Evidence relevant to guidelines for the investigation of breast symptoms, 2nd edn. National Breast Cancer Centre, (http://www.nbcc.org.au), Camperdown, Australia

National Comprehensive Cancer Network (NCCN) (2006) Breast Cancer. NCCN Clinical Practice Guidelines in Oncology, http://www.nccn.org, USA

National Comprehensive Cancer Network (NCCN) (2007a) Breast cancer screening and diagnosis guidelines. NCCN Clinical Practice Guidelines in Oncology, (http://www.nccn.org), USA

National Comprehensive Cancer Network (NCCN) (2007b) Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Clinical Practice Guidelines in Oncology edn. Clinical Practice Guidelines in Oncology, (http://www.nccn.org), USA

National Quality Management Committee of BreastScreen Australia (2004) Breastscreen Australia–National Accrediation Standards. 2004

NICE NCCfPC (2006c) Familial breast cancer - The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Update July 2006. NICE, http://www.nice.org.uk/CG041, UK

NHMRC (1999) Psychosocial clinical practice guideline. NHMRC, (http://www.nhmrc.health.gov.au), Australia

NHS Centre for Reviews, Dissemination (2000) Effective health care: Informing, communicating and sharing decision with people who have cancer. Latimer Trend & Company Ltd, Plymouth

NHSBSP (2001) Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening (vol NHSBSP Publication No. 50). NHS Cancer Screening Programmes, Sheffield

NICE (2005) NICE clinical guideline no 27: referral guidelines for suspected cancer. NICE, http://www.nice.org.uk/CG027, UK

NICE (2006a) Breast cancer: diagnosis and treatment. NICE, (http://www.nice.org.uk), UK

NICE (2006b) Image-guided vacuum-assisted excision biopsy of benign breast lesions. NICE, http://www.nice.org.uk/IPG156, UK

Nothacker M, Lelgemann M, Giersiepen K, Weinbrenner S (2007) Evidenzbericht 2007 zur S-3-Leitlinie Brustkrebsfrüherkennung in Deutschland, version 1.00 edn. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Band 31 http://www.aezq.de/publikationen0index/schriftenreihe/view, http://www.awmf-leitlinien.de, Berlin

O’Higgins N, Linos DA, Blichert-Toft M, Cataliotti L, de Wol C, Rochard F et al (2006) European guidelines for quality assurance in the surgical management of mammographically detected lesions. In: Perry N, Broeders M, de Wolf C, Toernberg S, Holland R, von Karsa L (eds) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for official publication of the European Communities, Luxembourg, pp 315–320

Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. European Communities Publication, Luxembourg

Raab-Schlesinger A, Eckel R, Engel J, Sauer H, Löhrs U, Molls M et al (2005) Metastasiertes Mammakarzinom: Keine Lebensverlängerung seit 20 Jahren. Aerzteblatt 102:B2280–B2288

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) (2008) Krebs in Deutschland 2003–2004. Häufigkeiten und Trends, 6. überarbeitet Auflage edn. Druckhaus Berlin-Mitte GmbH, Berlin

Schreer I, Katalinic A (2007) Is high quality breast imaging and diagnosis possible in a decentralized system? Breast Care 2:20–24. doi:10.1159/000099367 CrossRef

Schulz KD, Albert US, und die Mitglieder der Arbeitsgruppe “Konzertierte Aktion: Brustkrebs-Früherkennung in Deutschland (2003) Stufe 3 Leitlinie Brustkrebs-Früherkennung in Deutschland, 1 edn. Zuckschwerdt Verlag, München

Schwartz G, Veronesi U, Clough K, Dixon J, Fentima I, Heywang-Köbrunner S et al. (2006) Consensus Conference on Breast Conservation. Milan, Italy, 28 April–1 May 2005. Cancer 107:242–250. doi:10.1002/cncr.21988

Scottish Intecollegiate Guideline Network (SIGN) (2005) SIGN Scottish Intecollegiate Guideline Network. Management of breast cancer in women. SIGN, (http://www.sign.ac.uk), Edinburgh

Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED et al (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154–1157. doi:10.1016/S0140-6736(95)90982-6 PubMedCrossRef

Smith R, Saslow D, Sawyer K, Burke W, Costanza M, Evans W et al. Hendrick E, Eyre H, Sener S (2003) American Cancer Society guidelines for breast cancer screening. Update 2003. CA Cancer J Clin 53:141–169 (http://www.caonline.amcancersoc.org/cgi/content/full/53/3/141)

Smith R, Caleffi M, Albert US, Chen T, Duffy S, Franceschi D et al (2006) Breast cancer in limited-resource countries: early detection and access to care. Breast J 12:S16–S26. doi:10.1111/j.1075-122X.2006.00200.x PubMedCrossRef

Sobin L, Wittekind C (2002) UICC. TNM classification of malignant tumours, 6th edn. John Wiley & Sons, Inc. Publication, New York

The Association of Breast Surgery at BASO, RCoSoE (2005) Guidelines for the management of symptomatic breast disease. Eur J Surg Oncol 31:S1–S21

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R, Dowsett M, Fitzgibbons P, Hanna W, Langer A, McShane L, Paik S, Pegram M, Perez E, Press M, Rhodes A, Sturgeon C, Taube S, Tubbs R, Vance G, vanD V, Wheeler T, Hayes D (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:145. doi:10.1200/JCO.2007.11.4363 CrossRef

WHO (2003) Pathology and genetics of tumours of the breast and female genital organs. In: Tavassoli F, Devilee P (eds) World Health Organization (WHO) classification of tumours. IACR Press, Lyon, pp 9–112

World Health Organization (WHO) (2002) National Cancer Control Programs: policies and managerial guidelines, 2nd edn. Health and Development Networks (HDN), Geneva, Italy

Title: 2008 update of the guideline: early detection of breast cancer in Germany
Authors: Ute-Susann Albert
Helmut Altland
Volker Duda
Jutta Engel
Max Geraedts
Syvia Heywang-Köbrunner
Dieter Hölzel
Eva Kalbheim
Michael Koller
Klaus König
Rolf Kreienberg
Thorsten Kühn
Annette Lebeau
Irmgard Nass-Griegoleit
Werner Schlake
Rita Schmutzler
Ingrid Schreer
Hilde Schulte
Rüdiger Schulz-Wendtland
Uwe Wagner
Ina Kopp
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0450-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2009

Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics

A novel role of serum cytochrome c as a tumor marker in patients with operable cancer

Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer

Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling

The possible involvement of virus in breast cancer

Association of loss of BRCA1 expression with centrosome aberration in human breast cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials